Literature DB >> 16840410

Preventing ventilator-associated pneumonia in adults: sowing seeds of change.

Donald E Craven1.   

Abstract

Ventilator-associated pneumonia (VAP), a major cause of ICU infection, results in high morbidity, mortality, and health-care costs. Multiple risk factors for VAP involve complex host factors and ubiquitous pathogens that require several different types of prevention strategies. Prevention efforts should focus on reducing bacterial colonization, and limiting aspiration, antibiotic exposure, and use of invasive devices. Although evidence-based prevention guidelines are available, they are lengthy, often ignored, and not implemented. New insights into the barriers to implementation of effective prevention programs are emerging. This article provides highlights from recent guidelines and publications discussing VAP prevention strategies and examines barriers to their implementation. Prevention and implementation of cost-effective strategies to reduce risk and improve patient outcomes should be prioritized. Clearly, prevention programs should be population specific and may vary among hospitals, but a multidisciplinary prevention team led by a "champion" is recommended to help set priorities, benchmarking goals, analyze data, and sow the seeds of change for risk reduction.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16840410     DOI: 10.1378/chest.130.1.251

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  26 in total

1.  Who Gets Early Tracheostomy?: Evidence of Unequal Treatment at 185 Academic Medical Centers.

Authors:  Joshua J Shaw; Heena P Santry
Journal:  Chest       Date:  2015-11       Impact factor: 9.410

2.  Prevention of VAP: the whole is more than the sum of its parts.

Authors:  Thiago Lisboa; Marin H Kollef; Jordi Rello
Journal:  Intensive Care Med       Date:  2008-04-17       Impact factor: 17.440

3.  Probiotic prophylaxis of ventilator-associated pneumonia: a blinded, randomized, controlled trial.

Authors:  Lee E Morrow; Marin H Kollef; Thomas B Casale
Journal:  Am J Respir Crit Care Med       Date:  2010-06-03       Impact factor: 21.405

4.  Hemolytic phospholipase C inhibition protects lung function during Pseudomonas aeruginosa infection.

Authors:  Matthew J Wargo; Maegan J Gross; Sathish Rajamani; Jenna L Allard; Lennart K A Lundblad; Gilman B Allen; Michael L Vasil; Laurie W Leclair; Deborah A Hogan
Journal:  Am J Respir Crit Care Med       Date:  2011-05-11       Impact factor: 21.405

Review 5.  Bugs or drugs: are probiotics safe for use in the critically ill?

Authors:  Lindsay M Urben; Jennifer Wiedmar; Erica Boettcher; Rodrigo Cavallazzi; Robert G Martindale; Stephen A McClave
Journal:  Curr Gastroenterol Rep       Date:  2014

6.  Nosocomial outbreak of carbapenem-resistant Acinetobacter baumannii in intensive care units and successful outbreak control program.

Authors:  Won Suk Choi; Su Hyun Kim; Eun Gyong Jeon; Myeung Hee Son; Young Kyung Yoon; Jung-Yeon Kim; Mi Jeong Kim; Jang Wook Sohn; Min Ja Kim; Dae Won Park
Journal:  J Korean Med Sci       Date:  2010-06-17       Impact factor: 2.153

Review 7.  Intensive Care Unit-acquired infection as a side effect of sedation.

Authors:  Saad Nseir; Demosthenes Makris; Daniel Mathieu; Alain Durocher; Charles-Hugo Marquette
Journal:  Crit Care       Date:  2010-03-15       Impact factor: 9.097

8.  Intensive care unit management of patients with stroke.

Authors:  Sebastian Schulz-Stübner
Journal:  Curr Treat Options Neurol       Date:  2007-11       Impact factor: 3.598

Review 9.  Antibiotic consumption and ventilator-associated pneumonia rates, some parallelism but some discrepancies.

Authors:  David Nora; Pedro Póvoa
Journal:  Ann Transl Med       Date:  2017-11

10.  A randomized trial of chlorhexidine gluconate on oral bacterial pathogens in mechanically ventilated patients.

Authors:  Frank A Scannapieco; Jihnhee Yu; Krishnan Raghavendran; Angela Vacanti; Susan I Owens; Kenneth Wood; Joseph M Mylotte
Journal:  Crit Care       Date:  2009-07-15       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.